Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

Common Genetic Variations Predict Patient Response to Novel Beta Blocker

Therapy

TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among heart failure patients with very favorable genotypes, according to results of a large DNA study presented today as a poster at the annual meeting of the Heart Failure Society of America. Researchers found that common genetic variations can predict which heart failure patients will have the greatest therapeutic response to bucindolol.

ARCA biopharma has submitted a New Drug Application (NDA) for bucindolol to the U.S. Food and Drug Administration for the treatment of chronic heart failure.

"The ability to predict patient response to bucindolol makes it easier for physicians to match the right patient to the right medicine, potentially avoiding months of trial-and-error therapy and helping very sick heart failure patients achieve better outcomes sooner," said Christopher O'Connor, M.D., Director of the Heart Center at Duke University Medical Center and presenter of the study. "This data brings us much closer to realizing the benefits of personalized medicine in heart failure."

The prospectively-designed DNA sub-study included more than 1,000 patients enrolled in the Beta-Blocker Evaluation of Survival Trial (BEST), the largest heart failure mortality trial conducted primarily in the United States. Researchers evaluated therapeutic response to bucindolol among patients with genetic variations, or polymorphisms, in two adrenergic receptors that help regulate cardiac function: beta 1 389 Arg/Gly and alpha 2c 322-325 WT/Del. Researchers identified three distinct genotypes that predict the effect of bucindolol: very favorable (47% of BEST patients), favorable (40%) and unfavorable (13%).

In the study, patients with the very favorable genotype
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of ... Cassian Yee , M.D., Professor, Department of Melanoma ... of Texas MD Anderson Cancer Center joined its scientific ... Immunology, Division of Cancer Medicine, and Director, Solid Tumor ... University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... GA (PRWEB) May 06, 2015 ... based on the products of cells grown under ... its 105F immunomodulatory treatment candidate for melanoma during ... Meeting, taking place May 6-9, 2015 in Atlanta, ... multipotent cells produce a soluble material with anti-oncologic ...
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID and sample ... major content upgrade to its bestselling, Commercial Off-The-Shelf (COTS) ... a significant advancement of FreezerPro® system , ... also simplifying , New FreezerPro® VM ... Download available immediately for free to “Gold” support subscribers ...
(Date:5/5/2015)... 5, 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens,  today announced that ... of America Merrill Lynch 2015 Health Care Conference on May ... Encore at the Wynn, Las Vegas NV. ... will be available through the investor relations section of Roka ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2RURO Releases version 7 of FreezerPro® software 2
... Oriental,Bioengineering (NYSE: AOB ) announced today that ... decision to cancel its,convertible preferred stock offering at ... resulting in terms that were not acceptable to,the ... made in this press release are forward-looking and ...
... 5 Cardiac Science,Corporation (Nasdaq: CSCX ... diagnosis,resuscitation, rehabilitation, and informatics products, announced today,that ... Needham & Company Biotechnology,and Medical Technology Conference ... senior vice president and chief financial officer, ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced ... NF-kappa B Decoy (NF-kB Decoy) program, which includes ... (TFT). NF-kB Transcription Factor Decoy inhibits NF-kappa B, ... such as inflammatory,bowel disease (IBD), eczema, rheumatoid arthritis, ...
Cached Biology Technology:Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 3
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... tiger snakes stranded for thousands of years on tiny islands ... twice the size of their mainland cousins. Now, new research ... of these elapids was driven by the need to have ... at 35 inches (89 cm) long, patrol swampy areas in ...
... CHAMPAIGN, Ill. Miscanthus grasses are used in ... fuels. They also belong to a prominent grass family that ... maps of Miscanthus sinensis (an ornamental that ... biofuels crop) are a first step toward sequencing the ...
... 15, 2012) This fall, Drexel Environmental Science students will ... locally and across the globe as a result of ... Natural Sciences. Out of the affiliation comes the Department ... will work and learn among some of the world,s ...
Cached Biology News:Big-mouthed babies drove the evolution of giant island snakes 2Big-mouthed babies drove the evolution of giant island snakes 3Maps of Miscanthus genome offer insight into grass evolution 2Maps of Miscanthus genome offer insight into grass evolution 3New museum-university partnership ushers in new era of environmental science education 2
... revolutionizes imaging software for the microscopy ... microscopes, cameras, components and peripherals with ... tools. Its intuitive interface simplifies workflow ... while providing powerful features such as ...
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... incorporates the critical design features demanded by ... research. The Series 4000 delivers improved performance, ... discoveries to biomarker assays all on the ... to fit into the research plans of ...
Biology Products: